| EER | ENST | ENSG | GeneName | Region | Repeat | dsRNA structure | | chr17:43131798-43131998:+ | ENST00000356906.6 | ENSG00000198496.9 | NBR2 | ncRNA_intronic | AluSz6 | chr17:43131798-43131998:+.alignment |
| chr17:43131798-43131998:+ | ENST00000460115.4 | ENSG00000198496.9 | NBR2 | ncRNA_intronic | AluSz6 | chr17:43131798-43131998:+.alignment |
| chr17:43131798-43131998:+ | ENST00000467245.4 | ENSG00000198496.9 | NBR2 | ncRNA_intronic | AluSz6 | chr17:43131798-43131998:+.alignment |
| chr17:43132844-43133905:+ | ENST00000467245.4 | ENSG00000198496.9 | NBR2 | ncRNA_exonic | AluY,MER5A,MIR,AluSz | chr17:43132844-43133905:+.alignment |
| chr17:43137102-43138121:+ | ENST00000356906.6 | ENSG00000198496.9 | NBR2 | ncRNA_intronic | L1PA5,AluSz,AluSq2 | chr17:43137102-43138121:+.alignment |
| chr17:43137102-43138121:+ | ENST00000460115.4 | ENSG00000198496.9 | NBR2 | ncRNA_intronic | L1PA5,AluSz,AluSq2 | chr17:43137102-43138121:+.alignment |
| chr17:43137102-43138121:+ | ENST00000467245.4 | ENSG00000198496.9 | NBR2 | ncRNA_intronic | L1PA5,AluSz,AluSq2 | chr17:43137102-43138121:+.alignment |
| chr17:43139363-43139887:+ | ENST00000356906.6 | ENSG00000198496.9 | NBR2 | ncRNA_exonic | L1PREC2,AluSg4 | chr17:43139363-43139887:+.alignment |
| chr17:43139363-43139887:+ | ENST00000460115.4 | ENSG00000198496.9 | NBR2 | ncRNA_exonic | L1PREC2,AluSg4 | chr17:43139363-43139887:+.alignment |
| chr17:43141516-43143272:+ | ENST00000467245.4 | ENSG00000198496.9 | NBR2 | ncRNA_exonic | (TG)n,MIRb,AluY,(AT)n,AluSx,(TATT)n | chr17:43141516-43143272:+.alignment |
| chr17:43146340-43152964:+ | ENST00000467245.4 | ENSG00000198496.9 | NBR2 | ncRNA_intronic | A-rich,(AAAT)n,MIR3,AluY,AluSp,LTR88b,AluSx1,L2c,LTR7C,MIRb,AluSx3,AluSz6,AluJr,OldhAT1,L2,AluJb,MER81,AluSz | chr17:43146340-43152964:+.alignment |
| ID_events | cancer | TypeID | ImmuneCell | P | R | CorrelationPlot |
| chr17:43146340-43152964:+ | BLCA | EER | Dendritic_cells_activated | 3.1618e-02 | -0.1674 |  |
| ENSG00000198496.9,NBR2 | BLCA | EAG | Macrophages_M1 | 4.1926e-03 | 0.2079 |  |
| chr17:43139363-43139887:+ | BRCA | EER | Macrophages_M2 | 4.7232e-02 | -0.2380 |  |
| chr17:43146340-43152964:+ | BRCA | EER | T_cells_CD8 | 1.8562e-02 | -0.1826 |  |
| ENSG00000198496.9,NBR2 | BRCA | EAG | T_cells_regulatory_(Tregs) | 5.3960e-03 | -0.1724 | .ENSG00000198496.9,NBR2.png) |
| chr17:43146340-43152964:+ | CESC | EER | Dendritic_cells_resting | 1.6100e-02 | -0.2635 |  |
| ENSG00000198496.9,NBR2 | CESC | EAG | Dendritic_cells_resting | 7.0719e-03 | -0.2678 |  |
| ENSG00000198496.9,NBR2 | CHOL | EAG | NK_cells_resting | 4.9978e-02 | 0.4044 |  |
| ENSG00000198496.9,NBR2 | COAD | EAG | Dendritic_cells_activated | 2.2778e-04 | 0.4775 |  |
| chr17:43146340-43152964:+ | ESCA | EER | Mast_cells_resting | 2.4164e-02 | 0.2265 |  |
| ENSG00000198496.9,NBR2 | ESCA | EAG | T_cells_regulatory_(Tregs) | 2.5806e-02 | -0.1933 | .ENSG00000198496.9,NBR2.png) |
| chr17:43139363-43139887:+ | GBM | EER | Eosinophils | 3.2393e-02 | 0.4472 |  |
| ENSG00000198496.9,NBR2 | GBM | EAG | T_cells_CD4_memory_resting | 1.5208e-03 | 0.4248 |  |
| ENSG00000198496.9,NBR2 | HNSC | EAG | T_cells_CD4_memory_resting | 9.7408e-06 | 0.5256 |  |
| chr17:43146340-43152964:+ | KIRP | EER | T_cells_regulatory_(Tregs) | 3.0166e-02 | -0.2169 | .chr17_43146340-43152964_+.png) |
| ENSG00000198496.9,NBR2 | KIRP | EAG | T_cells_regulatory_(Tregs) | 4.2871e-02 | -0.1800 | .ENSG00000198496.9,NBR2.png) |
| chr17:43146340-43152964:+ | LAML | EER | Mast_cells_activated | 1.3604e-02 | -0.3309 |  |
| ENSG00000198496.9,NBR2 | LAML | EAG | T_cells_follicular_helper | 1.0309e-02 | 0.2769 |  |
| chr17:43146340-43152964:+ | LGG | EER | T_cells_CD4_naive | 2.3452e-02 | 0.2361 |  |
| ENSG00000198496.9,NBR2 | LGG | EAG | T_cells_follicular_helper | 2.1816e-03 | 0.2484 |  |
| ENSG00000198496.9,NBR2 | LUAD | EAG | Plasma_cells | 3.6351e-02 | -0.1557 |  |
| ENSG00000198496.9,NBR2 | LUSC | EAG | B_cells_naive | 2.3884e-02 | 0.1882 |  |
| ENSG00000198496.9,NBR2 | PCPG | EAG | Macrophages_M0 | 2.1915e-02 | 0.4970 |  |
| ENSG00000198496.9,NBR2 | PRAD | EAG | Neutrophils | 2.7709e-02 | 0.2774 |  |
| ENSG00000198496.9,NBR2 | SARC | EAG | Mast_cells_resting | 3.0141e-02 | 0.3476 |  |
| chr17:43132844-43133905:+ | STAD | EER | NK_cells_activated | 1.6692e-02 | 0.2517 |  |
| chr17:43137102-43138121:+ | STAD | EER | T_cells_CD8 | 2.4211e-03 | 0.5898 |  |
| chr17:43139363-43139887:+ | STAD | EER | T_cells_CD8 | 1.7598e-02 | 0.2830 |  |
| chr17:43141516-43143272:+ | STAD | EER | Macrophages_M0 | 2.1567e-02 | -0.2987 |  |
| ENSG00000198496.9,NBR2 | STAD | EAG | Eosinophils | 4.3198e-02 | -0.1293 |  |
| ENSG00000198496.9,NBR2 | TGCT | EAG | NK_cells_activated | 1.3524e-02 | 0.4388 |  |
| ENSG00000198496.9,NBR2 | THCA | EAG | T_cells_CD4_memory_activated | 2.6809e-02 | -0.1602 |  |
| ENSG00000198496.9,NBR2 | THYM | EAG | B_cells_naive | 3.8894e-02 | -0.2720 |  |
| ENSG00000198496.9,NBR2 | UCEC | EAG | T_cells_follicular_helper | 4.2177e-02 | -0.2701 |  |
| ENSG00000198496.9,NBR2 | UCS | EAG | Dendritic_cells_activated | 3.3424e-02 | 0.4771 |  |
| ID_events | cancer | HallmarkType | Type | P | R | CorrelationPlot |
| ENSG00000198496.9,NBR2 | BLCA | GSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING | EAG | 6.8188e-06 | 0.3215 |  |
| chr17:43146340-43152964:+ | BLCA | GSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING | EER | 1.2636e-02 | 0.1938 |  |
| chr17:43146340-43152964:+ | BRCA | GSVA_HALLMARK_ANDROGEN_RESPONSE | EER | 2.7134e-03 | 0.2313 |  |
| ENSG00000198496.9,NBR2 | CESC | GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING | EAG | 5.5484e-03 | 0.2754 |  |
| chr17:43146340-43152964:+ | CESC | GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING | EER | 1.1172e-05 | 0.4617 |  |
| ENSG00000198496.9,NBR2 | COAD | GSVA_HALLMARK_PEROXISOME | EAG | 1.2788e-03 | -0.4234 |  |
| chr17:43146340-43152964:+ | ESCA | GSVA_HALLMARK_MYOGENESIS | EER | 1.1318e-02 | 0.2536 |  |
| ENSG00000198496.9,NBR2 | GBM | GSVA_HALLMARK_ANGIOGENESIS | EAG | 1.3172e-02 | -0.3385 |  |
| chr17:43139363-43139887:+ | GBM | GSVA_HALLMARK_APICAL_SURFACE | EER | 4.5215e-02 | -0.4214 |  |
| ENSG00000198496.9,NBR2 | HNSC | GSVA_HALLMARK_TGF_BETA_SIGNALING | EAG | 3.7811e-04 | 0.4341 |  |
| ENSG00000198496.9,NBR2 | KIRP | GSVA_HALLMARK_P53_PATHWAY | EAG | 3.0117e-02 | -0.1925 |  |
| chr17:43146340-43152964:+ | KIRP | GSVA_HALLMARK_PROTEIN_SECRETION | EER | 6.3129e-03 | 0.2714 |  |
| chr17:43146340-43152964:+ | LAML | GSVA_HALLMARK_UV_RESPONSE_DN | EER | 4.5875e-02 | 0.2704 |  |
| ENSG00000198496.9,NBR2 | LAML | GSVA_HALLMARK_E2F_TARGETS | EAG | 1.1160e-02 | 0.2740 |  |
| chr17:43146340-43152964:+ | LGG | GSVA_HALLMARK_HEDGEHOG_SIGNALING | EER | 2.2735e-03 | 0.3144 |  |
| ENSG00000198496.9,NBR2 | LGG | GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY | EAG | 7.0490e-05 | -0.3187 |  |
| ENSG00000198496.9,NBR2 | LUAD | GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE | EAG | 4.4088e-02 | 0.1498 |  |
| ENSG00000198496.9,NBR2 | LUSC | GSVA_HALLMARK_MYC_TARGETS_V2 | EAG | 3.1220e-03 | -0.2447 |  |
| ENSG00000198496.9,NBR2 | OV | GSVA_HALLMARK_COAGULATION | EAG | 1.2563e-03 | 0.2654 |  |
| chr17:43146340-43152964:+ | OV | GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB | EER | 1.7747e-03 | 0.3166 |  |
| chr17:43139363-43139887:+ | OV | GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS | EER | 3.1641e-02 | 0.3321 |  |
| ENSG00000198496.9,NBR2 | SARC | GSVA_HALLMARK_MYC_TARGETS_V1 | EAG | 5.8968e-03 | -0.4330 |  |
| chr17:43137102-43138121:+ | STAD | GSVA_HALLMARK_ALLOGRAFT_REJECTION | EER | 4.9347e-02 | 0.4054 |  |
| chr17:43141516-43143272:+ | STAD | GSVA_HALLMARK_ALLOGRAFT_REJECTION | EER | 3.7011e-02 | 0.2722 |  |
| chr17:43146340-43152964:+ | STAD | GSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING | EER | 4.6905e-02 | 0.1509 |  |
| ENSG00000198496.9,NBR2 | STAD | GSVA_HALLMARK_ALLOGRAFT_REJECTION | EAG | 7.1638e-03 | 0.1714 |  |
| ENSG00000198496.9,NBR2 | TGCT | GSVA_HALLMARK_GLYCOLYSIS | EAG | 1.3871e-02 | 0.4374 |  |
| chr17:43146340-43152964:+ | THCA | GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING | EER | 8.5985e-04 | 0.2676 |  |
| ENSG00000198496.9,NBR2 | THCA | GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING | EAG | 8.4975e-06 | 0.3159 |  |
| ENSG00000198496.9,NBR2 | THYM | GSVA_HALLMARK_UV_RESPONSE_DN | EAG | 3.5373e-03 | 0.3770 |  |
| ENSG00000198496.9,NBR2 | UCEC | GSVA_HALLMARK_KRAS_SIGNALING_DN | EAG | 1.8321e-03 | 0.4039 |  |
| ENSG00000198496.9,NBR2 | UCS | GSVA_HALLMARK_G2M_CHECKPOINT | EAG | 4.8046e-03 | 0.6039 |  |
| ID_events | cancer | Drug | Type | P | R | CorrelationPlot |
| chr17:43146340-43152964:+ | BLCA | JW.7.52.1 | EER | 1.2510e-04 | 0.2942 |  |
| ENSG00000198496.9,NBR2 | BLCA | AICAR | EAG | 6.3207e-05 | -0.2875 |  |
| chr17:43146340-43152964:+ | BRCA | BMS.536924 | EER | 8.0167e-04 | 0.2585 |  |
| ENSG00000198496.9,NBR2 | BRCA | GSK.650394 | EAG | 4.8337e-02 | 0.1228 |  |
| chr17:43146340-43152964:+ | CESC | Bryostatin.1 | EER | 1.9373e-03 | 0.3354 |  |
| ENSG00000198496.9,NBR2 | CESC | AMG.706 | EAG | 1.4067e-02 | 0.2449 |  |
| ENSG00000198496.9,NBR2 | COAD | GSK.650394 | EAG | 1.6056e-04 | 0.4874 |  |
| ENSG00000198496.9,NBR2 | ESCA | DMOG | EAG | 3.6853e-05 | -0.3497 |  |
| chr17:43146340-43152964:+ | ESCA | Cyclopamine | EER | 6.8425e-05 | -0.3892 |  |
| ENSG00000198496.9,NBR2 | HNSC | Bortezomib | EAG | 3.8141e-04 | 0.4339 |  |
| ENSG00000198496.9,NBR2 | KIRP | GSK269962A | EAG | 6.2973e-04 | 0.3005 |  |
| chr17:43146340-43152964:+ | KIRP | CGP.60474 | EER | 6.4468e-04 | 0.3355 |  |
| ENSG00000198496.9,NBR2 | LAML | AZ628 | EAG | 5.7401e-03 | 0.2972 |  |
| chr17:43146340-43152964:+ | LAML | Bryostatin.1 | EER | 3.2388e-03 | 0.3901 |  |
| ENSG00000198496.9,NBR2 | LGG | Dasatinib | EAG | 3.5762e-05 | 0.3307 |  |
| chr17:43146340-43152964:+ | LGG | A.770041 | EER | 3.8278e-04 | 0.3626 |  |
| chr17:43146340-43152964:+ | LUAD | A.770041 | EER | 3.1766e-03 | 0.2459 |  |
| ENSG00000198496.9,NBR2 | LUAD | A.770041 | EAG | 1.3110e-02 | 0.1841 |  |
| ENSG00000198496.9,NBR2 | OV | Erlotinib | EAG | 2.4438e-04 | -0.3002 |  |
| chr17:43146340-43152964:+ | OV | Epothilone.B | EER | 8.0410e-03 | -0.2704 |  |
| chr17:43139363-43139887:+ | OV | CCT007093 | EER | 1.9788e-02 | 0.3584 |  |
| ENSG00000198496.9,NBR2 | PAAD | BIBW2992 | EAG | 3.8747e-02 | 0.2770 |  |
| ENSG00000198496.9,NBR2 | PRAD | AMG.706 | EAG | 1.0216e-02 | -0.3214 |  |
| ENSG00000198496.9,NBR2 | SARC | CCT007093 | EAG | 1.0488e-02 | -0.4052 |  |
| ENSG00000198496.9,NBR2 | SKCM | AMG.706 | EAG | 1.0944e-02 | -0.2700 |  |
| chr17:43132844-43133905:+ | STAD | GDC.0449 | EER | 3.6908e-02 | -0.2203 |  |
| chr17:43139363-43139887:+ | STAD | BMS.509744 | EER | 2.2529e-03 | -0.3593 |  |
| chr17:43141516-43143272:+ | STAD | CCT018159 | EER | 1.4546e-03 | -0.4052 |  |
| chr17:43137102-43138121:+ | STAD | AZD.2281 | EER | 2.6271e-02 | -0.4529 |  |
| chr17:43146340-43152964:+ | STAD | BIRB.0796 | EER | 2.6402e-04 | 0.2733 |  |
| ENSG00000198496.9,NBR2 | STAD | BMS.708163 | EAG | 2.7577e-03 | -0.1905 |  |
| ENSG00000198496.9,NBR2 | TGCT | MG.132 | EAG | 2.8958e-02 | -0.3925 |  |
| chr17:43146340-43152964:+ | THCA | CCT007093 | EER | 1.4249e-04 | -0.3037 |  |
| ENSG00000198496.9,NBR2 | THCA | Bexarotene | EAG | 1.1570e-04 | -0.2753 |  |
| ENSG00000198496.9,NBR2 | THYM | AS601245 | EAG | 1.0021e-02 | -0.3356 |  |
| ENSG00000198496.9,NBR2 | UCEC | GW.441756 | EAG | 2.7871e-05 | 0.5247 |  |
| ENSG00000198496.9,NBR2 | UCS | Bicalutamide | EAG | 1.2884e-02 | 0.5454 |  |